Advertisement

Topics

Companies Related to "Actuate gets expand clinical testing lead candidate" [Most Relevant Company Matches] RSS

23:20 EDT 15th June 2019 | BioPortfolio

Here are the most relevant search results for "Actuate gets expand clinical testing lead candidate" found in our extensive corporate database of over 50,000 company records.

Showing "Actuate gets expand clinical testing lead candidate" Companies 1–25 of 7,300+

Relevant

Amazentis SA

Amazentis SA is a life science company that employs today’s leading research and clinical science to develop the next generation of bioactive ingredients derived from nature for advanced therapeutic nutrition products. The Company’s lead product candidate, AMAZ-02, an oral formulation of Urolithin A, is planned to enter Phase 2 clinical testing d...


immatics biotechnologies GmbH

"immatics is a biopharmaceutical company from Tuebingen/Germany. With presently 40 employees immatics develops peptide-based therapeutic vaccines for oncology. The most advanced product candidate, IMA901, addresses the unmet medical need in renal cell carcinoma. Based on very encouraging results from a recently completed phase 1 trial, IMA901 will soon be transferred to phase 2 clinical testing. A...

Actuate Corporation


Teva Pharmaceutical Industries Ltd. & OncoGenex Pharmaceuticals, Inc.

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the le...

Bionovo

Bionovo is a publicly traded pharmaceutical company focused on discovering and developing drugs for women's health and cancer. Bionovo is a leader in systems-biology integration with candidates designed to address specific targets associated with the regulation of pathological conditions. The company is working simultaneously on two distinct discovery approaches, one focusing on pro-apoptotic ag...

Pipex

Pipex Pharmaceuticals, Inc. (“Pipex”) (OTC: BB: PPEX) is a development-stage, specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and autoimmune diseases. Our strategy is to exclusively in-license proprietary, clinical-stage drug candidates that have demonstrated clinical efficacy and to complete the further clinical testi...

Apothogen

IntraBiotics' mission is to combine clinical development with recognized commercial expertise for the development and commercialization of emerging drugs and commercial products. To achieve that mission, we strive to deliver medical benefits to patients, to offer professional challenges for employees and to provide competitive returns for investors.Key strategies include: Focus on the de...

RAPT Therapeutics, Inc.

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company develops highly selective small molecu...

Jennerex Biotherapeutics, Inc.

Jennerex Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of groundbreaking oncolytic immunotherapies for patients with life-threatening cancers. The company’s lead product candidate, Pexa-Vec (JX-594), is in mid-stage clinical development for the treatment of advanced primary liver cancer, ...

Phytomedics Inc.

Phytomedics, Inc. is a clinical stage biopharmaceutical company with a novel portfolio of drugs and consumer products solely derived from plant sources. Through this proprietary technology platform, the Company has produced a broad pipeline of lead product candidates, several of which are in clinical development. The company's lead candidate, PMI-001, is a novel, oral, disease modifying anti-rheu...

TorreyPines Therapeutics

We are a clinical stage biopharmaceutical company committed to discovering, developing and commercializing novel small molecules to treat diseases and disorders of the central nervous system (CNS). Our initial focus is on delivering potentially next generation therapies for chronic pain, including migraine, and cognitive disorders such as cognitive impairment associated with schizophrenia (CIAS) a...

resTORbio, Inc.

resTORbio, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio’s lead program is targeting the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases and conditions with an initial focus on conditions caus...

Molecular Insight Pharmaceuticals

Molecular Insight Pharmaceuticals, Inc. is focused on the research, development and commercialization of innovative molecular imaging pharmaceuticals and targeted radiotherapeutics to diagnose, treat and manage disease. The company's two lead compounds, Zemivaâ„¢ and Azedraâ„¢, are in advancing clinical programs. Molecular Insight has completed a Phase 2b clinical trial for its lead cardio...

Aerie Pharmaceuticals

Aerie Pharmaceuticals is a privately held, clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma. Aerie’s internal research and development engine has generated an innovative glaucoma pipeline. The Company’s lead product candidate, AR-12286, is a highly selective Rho-kinase (ROCK) inhibitor ...

Novacea

We are a biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. We currently have two clinical-stage oncology product candidates. Our lead product candidate, Asentar™ (DN-101), is in a Phase 3 clinical trial for the treatment of androgen-independent prostate cancer, or AIPC, also known as hormone-refractory prostate cancer. ...

Atopix Therapeutics Ltd

Atopix Therapeutics Limited is a privately held, clinical-stage, biopharmaceutical company based in Oxford, UK, with an innovative approach to allergy. The company is developing a novel class of oral anti-allergic medicines, called CRTH2 antagonists, to treat atopic dermatitis, asthma and allergic rhinitis. Its lead candidate is currently being studied in a Phase 2 clinical trial for severe atop...

Afferon Corporation

Afferon is a privately held pharmaceutical company building a specialty pharmaceutical business focused on urology. Afferon has completed the necessary pre-clinical work on its lead candidate, resiniferatoxin, and has shown proof of principle in Phase I/IIa human clinical trials in urinary urge incontinence and diabetic neuropathy pain. Several large Phase II trials are underway in the U.S. and ...

BIO RELIANCE

BioReliance is the world’s largest specialist provider of contract biologics safety testing, GMP manufacturing and pre-clinical and clinical testing services.

ALX Oncology

ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism, which is exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a fusion protein comprised of an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobuli...

Viventia Biotech Inc

Viventia Biotech Inc. is a biopharmaceutical company advancing a new generation of monoclonal antibody therapeutics designed to offer safer, more beneficial therapies for cancer patients. Viventia’s lead product candidate Proxinium™ continues on an aggressive clinical development schedule. Viventia has initiated a Phase II North American clinical trial and concurrently commenced a pivotal Phas...

Nascent Biotech Inc.

NBI is a biotechnology company developing human Monoclonal Antibodies (mAb’s) for immunotherapy of cancer. Its lead therapeutic candidate, Pritumumab, was the first human antibody ever developed to treat a cancer patient and has been validated in 249 patients in Japan. The company is now developing a new clinical protocol and Initial New Drug (IND) pa...

Consumer Product Testing Company, Inc.

Consumer Product Testing Company is a worldwide leader in the contract laboratory testing of cosmetics, personal care, pharmaceuticals, medical devices and specialty chemicals. Since 1975, our staff has assisted clients with their testing needs from conception to completion. The testing services offered include clinical safety & claims validation & research (dermatology, gynecology, ophthalmology,...

Urovant Sciences Ltd.

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Urovant’s lead product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist being evaluated for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinar...

Urovant Sciences

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Urovant’s lead product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist being evaluated for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinar...

Spirogen Ltd

Spirogen was founded in 2001 as a spin-out from several institutions including University College London.  Since that time, it has developed a novel class of highly potent cytotoxic warheads based on its proprietary pyrrolobenzodiazepines (PBDs), DNA minor groove binding agents, which bind and cross-link specific sites of DNA of the cancer cell.  This blocks the cancer cells’ div...


More From BioPortfolio on "Actuate gets expand clinical testing lead candidate"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks